ACCENT I - A Randomized, Double-blind, Placebo-controlled Trial of Anti-TNFa Chimeric Monoclonal Antibody (Infliximab, Remicade) in the Long-term Treatment of Patients With Moderately to Severely Active Crohn's Disease
收藏DataCite Commons2026-03-02 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00004618/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
This is a study of infliximab (Remicade) in subjects with Crohn's disease
提供机构：
Vivli
创建时间：
2019-09-19
